First-line
-
Doublet chemotherapy in combination with a biologic agent has been a standard of care in patients with metastatic colorectal cancer for over a decade. The evidence for a “lighter” treatment approach is limited to mono-chemotherapy plus bevacizumab in the RAS unselected population. Anti-EGFR antibodies have activity as monotherapy or in combination with chemotherapy in RAS wildtype metastatic colorectal cancer.
9p vimahuateng 26-11-2021 8 0 Download
-
Extensive-disease small-cell lung cancer (ED-SCLC) is characterized by rapid progression and relapse, despite high initial response rates to chemotherapy. The primary objective of this trial was to demonstrate the noninferiority of amrubicin and cisplatin (AP) combination therapy compared with the standard first-line regimen of etoposide and cisplatin (EP) for previously untreated ED-SCLC in a Chinese population.
8p vinaypyidaw2711 26-08-2020 15 1 Download
-
Pancreatic cancer has a poor prognosis and few choices of therapy. For patients with adequate performance status, FOLFIRINOX or gemcitabine plus nab-paclitaxel are preferred first-line treatment. 5-Fluorouracil (5-FU)–based therapy (e.g. FOLFIRI, OFF, or FOLFOX) are often used in patients who previously received gemcitabine-based regimens.
9p vidhaka2711 31-07-2020 9 1 Download
-
First-line treatment with FOLFOXIRI plus bevacizumab (BEV) is highly effective and regarded as one of the standards-of-care for patients with metastatic colorectal cancer (mCRC), despite the high incidence of neutropenia and diarrhea as side effects.
9p vidhaka2711 31-07-2020 12 1 Download
-
In recent years, systemic chemotherapy and molecular targeted therapy have become standard firstline treatments for locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC).
7p vidhaka2711 31-07-2020 8 1 Download
-
The optimal duration of firstline chemotherapy in metastatic esophagogastric cancer is unknown. In most clinical trials therapy was given until tumour progression or limiting toxicity.
8p vidhaka2711 31-07-2020 7 1 Download
-
Up to 80% of breast cancer patients suffer from Cancer Related Cognitive Impairments (CRCI). Exercise is suggested as a potential supportive care option to reduce cognitive decline in cancer patients. This study will investigate the effects of a high-intensity interval endurance training (HIIT) on CRCI in breast cancer patients.
14p vimanila2711 25-06-2020 13 3 Download
-
The combination of nivolumab, a programmed death-1 (PD-1) targeted monoclonal antibody, with the cytotoxic T-lymphocyte antigen-4 (CTLA-4) targeted antibody, ipilimumab, represents a new standard of care in the first-line setting for patients with intermediate- and poor-risk metastatic renal cell carcinoma (mRCC) based on recent phase III data.
9p vikuala271 13-06-2020 10 1 Download
-
Khoảng 60% bệnh nhân được điều trị bằng imatinib 400 mg trong ngày sau khi thất bại điều trị interferon-alpha sẽ đạt được một phản ứng di truyền tế bào lớn. Điều này là hoàn toàn trong 41% (Kantarjian et al 2002). CCyR đạt được trong 75% những người được điều trị với imatinib như firstline điều trị (O'Brien et al 2003).
36p meomap2 28-11-2011 64 5 Download